KLP Kapitalforvaltning AS Makes New Investment in Tempus AI, Inc. $TEM

KLP Kapitalforvaltning AS purchased a new position in Tempus AI, Inc. (NASDAQ:TEM) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 15,700 shares of the company’s stock, valued at approximately $998,000.

Several other institutional investors also recently added to or reduced their stakes in the business. Cherry Tree Wealth Management LLC acquired a new position in shares of Tempus AI in the first quarter valued at $31,000. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Tempus AI in the first quarter valued at $33,000. Continuum Advisory LLC acquired a new position in shares of Tempus AI in the first quarter valued at $39,000. Bartlett & CO. Wealth Management LLC raised its stake in shares of Tempus AI by 100.0% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 800 shares of the company’s stock valued at $39,000 after purchasing an additional 400 shares in the last quarter. Finally, Nemes Rush Group LLC acquired a new stake in shares of Tempus AI during the 1st quarter valued at about $39,000. 24.22% of the stock is owned by institutional investors.

Insider Buying and Selling at Tempus AI

In other news, CEO Eric P. Lefkofsky sold 332,500 shares of the company’s stock in a transaction on Thursday, September 25th. The stock was sold at an average price of $76.56, for a total transaction of $25,456,200.00. Following the transaction, the chief executive officer owned 9,141,032 shares of the company’s stock, valued at $699,837,409.92. This represents a 3.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Theodore Leonsis sold 44,000 shares of the stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $69.90, for a total value of $3,075,600.00. Following the completion of the transaction, the director directly owned 86,756 shares in the company, valued at $6,064,244.40. The trade was a 33.65% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 933,662 shares of company stock valued at $68,070,993 over the last ninety days. Company insiders own 26.27% of the company’s stock.

Tempus AI Price Performance

Tempus AI stock opened at $91.91 on Thursday. The company has a debt-to-equity ratio of 2.58, a quick ratio of 1.43 and a current ratio of 1.54. The firm has a market cap of $15.97 billion, a P/E ratio of -77.24 and a beta of 4.87. The business’s fifty day moving average is $81.00 and its two-hundred day moving average is $65.55. Tempus AI, Inc. has a 52 week low of $31.36 and a 52 week high of $104.32.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Friday, August 8th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. The company had revenue of $314.64 million for the quarter, compared to analyst estimates of $296.84 million. Tempus AI had a negative return on equity of 122.86% and a negative net margin of 20.98%.The business’s revenue was up 89.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($6.86) earnings per share. Tempus AI has set its FY 2025 guidance at EPS. Equities research analysts forecast that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on TEM shares. Needham & Company LLC reiterated a “buy” rating and set a $70.00 target price on shares of Tempus AI in a research report on Friday, August 8th. Piper Sandler reiterated a “neutral” rating on shares of Tempus AI in a research report on Friday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tempus AI in a research report on Wednesday, October 8th. Morgan Stanley upped their price target on Tempus AI from $65.00 to $68.00 and gave the company an “overweight” rating in a research report on Tuesday, August 12th. Finally, Bank of America upped their price target on Tempus AI from $68.00 to $70.00 and gave the company a “neutral” rating in a research report on Wednesday, June 25th. Seven equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $71.83.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.